Laboratory costs of diagnosing TB in a high multidrug-resistant TB setting.
作者信息
Cates L, Crudu V, Codreanu A, Ciobanu N, Fosburgh H, Cohen T, Menzies N A
机构信息
Harvard T H Chan School of Public Health, Boston, MA, USA.
Chiril Draganiuc Institute of Phthisiopneumology, Chisinau, Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Moldova.
出版信息
Int J Tuberc Lung Dis. 2021 Mar 1;25(3):228-230. doi: 10.5588/ijtld.20.0586.
Abstract
摘要
相似文献
1
Laboratory costs of diagnosing TB in a high multidrug-resistant TB setting.
Int J Tuberc Lung Dis. 2021 Mar 1;25(3):228-230. doi: 10.5588/ijtld.20.0586.
2
Multidrug-resistant tuberculous orchiepididymitis: a brief case report.
Rev Inst Med Trop Sao Paulo. 2023 Dec 4;65:e61. doi: 10.1590/S1678-9946202365061. eCollection 2023.
3
The "source" of drug-resistant TB outbreaks.
Science. 2006 Oct 20;314(5798):419-20. doi: 10.1126/science.314.5798.419c.
4
Trench warfare in a battle with TB.
Science. 2008 Jul 18;321(5887):362-4. doi: 10.1126/science.321.5887.362.
5
Drug Resistance of Mycobacterium tuberculosis Complex in a Rural Setting, Angola.
Emerg Infect Dis. 2018 Mar;24(3):569-572. doi: 10.3201/eid2403.171562.
6
Drug-resistant tuberculosis: pediatric guidelines.
Pediatr Infect Dis J. 2011 Jun;30(6):501-5. doi: 10.1097/INF.0b013e31820b583d.
7
Costs of Tuberculosis at 3 Treatment Centers, Canada, 2010-2016.
Emerg Infect Dis. 2022 Sep;28(9):1814-1823. doi: 10.3201/eid2809.220092.
8
Multidrug-resistant tuberculosis in Imo State, Southeast, Nigeria.
Niger J Clin Pract. 2020 Aug;23(8):1172-1177. doi: 10.4103/njcp.njcp_192_19.
9
Prevalence of pyrazinamide resistance across the spectrum of drug resistant phenotypes of Mycobacterium tuberculosis.
Tuberculosis (Edinb). 2016 Jul;99:128-130. doi: 10.1016/j.tube.2016.05.003. Epub 2016 May 30.
10
Drug-resistant tuberculosis: what is to be done?
Chest. 2009 Aug;136(2):333-335. doi: 10.1378/chest.09-0785.
引用本文的文献
1
A Comprehensive Review of the Diagnostics for Pediatric Tuberculosis Based on Assay Time, Ease of Operation, and Performance.
Microorganisms. 2025 Jan 16;13(1):178. doi: 10.3390/microorganisms13010178.
2
Cost-effectiveness of targeted next-generation sequencing (tNGS) for detection of tuberculosis drug resistance in India, South Africa and Georgia: a modeling analysis.
EClinicalMedicine. 2024 Dec 24;79:103003. doi: 10.1016/j.eclinm.2024.103003. eCollection 2025 Jan.
3
Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis.
PLoS Med. 2024 May 3;21(5):e1004401. doi: 10.1371/journal.pmed.1004401. eCollection 2024 May.
4
Aptamer-Based Diagnostic Systems for the Rapid Screening of TB at the Point-of-Care.
Diagnostics (Basel). 2021 Jul 28;11(8):1352. doi: 10.3390/diagnostics11081352.
本文引用的文献
1
Assessing tuberculosis control priorities in high-burden settings: a modelling approach.
Lancet Glob Health. 2019 May;7(5):e585-e595. doi: 10.1016/S2214-109X(19)30037-3. Epub 2019 Mar 20.
2
Cost analysis of rapid diagnostics for drug-resistant tuberculosis.
BMC Infect Dis. 2018 Mar 2;18(1):102. doi: 10.1186/s12879-018-3013-0.
3
Reducing the price of treatment for multidrug-resistant tuberculosis through the Global Drug Facility.
Bull World Health Organ. 2015 Apr 1;93(4):279-82. doi: 10.2471/BLT.14.145920. Epub 2015 Feb 27.
4
Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review.
Pharmacoeconomics. 2015 Sep;33(9):939-55. doi: 10.1007/s40273-015-0279-6.
5
Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005-2007.
Emerg Infect Dis. 2014 May;20(5):812-21. doi: 10.3201/eid2005.131037.
6
Costs of patients hospitalized for multidrug-resistant tuberculosis.
Int J Tuberc Lung Dis. 2004 Aug;8(8):1012-6.
Zotero 插件